GlassScriptPhysician profile
Debashree Tosh-Mitchell
NPI 1548433535
$5,418.49
in general payments reported to CMS, 2019-2025
38 companies · $626 in 2025
The $626 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $627 · 2021: $942 · 2022: $694 · 2023: $884 · 2024: $926 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,054.98 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $699.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.59 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $299.36 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $281.15 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $248.59 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $225.18 | 2019-2025 | Xolair |
| Jazz Pharmaceuticals INC. | $224.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $195.13 | 2019-2025 | Zerbaxa |
| Sunovion Pharmaceuticals INC. | $186.73 | 2019-2020 | |
| Electromed, INC. | $163.75 | 2021-2024 | Smartvest |
| Abbvie INC. | $161.07 | 2021-2024 | Teflaro, Avycaz |
| Novocure INC. | $130.53 | 2024 | Optune Lua (Novottf-200t) |
| Insmed, INC. | $119.51 | 2019-2025 | Arikayce |
| Genzyme Corporation | $95.02 | 2020-2024 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debashree Tosh-Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.